Rituximab Treatment of Focal Segmental Glomerulosclerosis

Phase 2 Withdrawn National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Genentech, Inc. · collab Indiana University · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the approved drug, rituximab, is effective in the treatment of focal segmental glomerulosclerosis (FSGS)

Timeline

Start: 2008-01
Primary completion: 2009-12
Completion: 2009-12

Outcome

Outcome not reported

Stopped: “Problems with drug supply”

Publications

Background Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med. 2006 May 4;354(18):1961-3. doi: 10.1056/NEJMc055495. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous